Comparison of 1064 nm picosecond laser alone and combination with fractional 1064 nm picosecond laser for tattoo removal

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20201027006

Enrollment

Unknown

Registered

2020-10-27

Start date

2020-07-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Black tattoo on the body size from 1x1 cm to 10x10 cm Males and females aged 18&#45

Interventions

Perform 1064 nm picosecond laser on one side of tattoo,Perform 1064 nm picosecond laser combine with fractional 1064 nm picosecond on another side of tattoo

Experimental Device,Experimental Device

1064 nm picosecond laser,1064 nm picosecond laser combine with fractional 1064 nm picosecond laser

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Healthy males and females aged 18-55 years with the presence of black tattoos on the trunk and extremities size from 1x1 cm to 10x10 cm 2. Fitzpatrick skin types III to V 3. Willing to participate in the study and signed the inform consent

Exclusion criteria

Exclusion criteria: 1. Pregnancy or breastfeeding 2. History of overtattooing with colors other than black 3. History of keloid or hypertrophic scar 4. Performed laser treatments, dermabrasion, chemical peeling on tattooed skin within 6 months 5. Systemic retinoids within 6 months 6. History of photosensitivity 7. Skin infection around tattoo area

Design outcomes

Primary

Measure	Time frame
Tattoo clearance Week 0, 4, 8, 12 4 point scale tattoo clearance using standardized digital photographs	—

Secondary

Measure	Time frame
Skin texture Week 0, 4, 8, 12 Antera 3D,Scar assessment Week 4, 8, 12 0= none, 1= mild, 2=moderate, 3=severe,PIH assessment Week 4, 8, 12 0= none, 1= mild, 2=moderate, 3=severe,Patient satisfaction index Week 4, 8, 12 0 dissatisfied, 1-25% slightly satisfied, 26-50% moderately satisfied, 51-75% very satisfied, 76-100,Pain score Week 0,4,8 VAS 0-10,Adverse effects Week 0,4,8,12 Physician and patients	—

Measure

Time frame

Skin texture Week 0, 4, 8, 12 Antera 3D,Scar assessment Week 4, 8, 12 0= none, 1= mild, 2=moderate, 3=severe,PIH assessment Week 4, 8, 12 0= none, 1= mild, 2=moderate, 3=severe,Patient satisfaction index Week 4, 8, 12 0 dissatisfied, 1-25% slightly satisfied, 26-50% moderately satisfied, 51-75% very satisfied, 76-100,Pain score Week 0,4,8 VAS 0-10,Adverse effects Week 0,4,8,12 Physician and patients

—

Countries

Thailand

Contacts

Public ContactPassaraporn Vongchansathapat

Division of dermatology, Chulabhorn International College of Medicine, Thammasat University

passarapornv@gmail.com0875187799

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026